TABLE 4.
Dysregulation of LINC00511 in different cancers (TNTP: tumor and non-tumor pairs of tissues).
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Upregulated/Oncogene | Huh7, Hep3B | - | RAB27B | There seems to be a link between the creation of invadopodia and the generation of exosomes and LINC00511 dysregulation. In HCC, LINC00511 could be a treatment option | Peng et al. (2021) |
| Upregulated/Oncogene | SMCC7721, HepG2, Huh7, Hep3B | LINC00511/miR195/EYA1 axis | miR195/EYA1 | A prospective therapeutic option for the detection of HCC has been provided by LINC00511 that interacted with EYA1 to accelerate HCC formation through miR-195 | Hu et al. (2020a) | |
| Upregulated/Oncogene | 127 TNTPs/LO2, Hep3B, HepG2, SMMC-7721, MHCC97H, Huh7, HCCLM3 | - | miR-424 | LINC00511 may have a significant impact on how HCC develops, and that it will also act as a viable prognostic and therapeutic target. | Wang et al. (2019a) | |
| Liver Hepatocellular Carcinoma (LIHC) | Upregulated/Oncogene | LO2, MHCC-97H, Huh7, HCC-LM3, Hep3B, MHCC-97L, Huh6 | - | miRNA-29c | Through boosting tumor cell proliferative ability, LINC00511 worsens LIHC’s development. A predictive marker for LIHC could be LINC00511 | Liu et al. (2019) |
| Osteosarcoma (OS) | Upregulated/Oncogene | 24 TNTPs/SW1353, U2OS | LINC00511/miR-185-3p/E2F1 axis | miR-185-3p/E2F1 | As an oncogenic RNA, LINC00511 leads to the formation and spread of tumor cells. The LINC00511/miR-185-3p/E2F1 axis may be extremely important for the onset of osteosarcoma | Xu et al. (2020) |
| Upregulated/Oncogene | 30 TNTPs s/(MG‐63, Saos‐2, U2OS, HOS, NHOst | - | miR‐765 | Via substantially controlling the production of miR-765, aberrant transcription of LINC00511 boosted osteosarcoma cell tumorigenesis and motility | Yan et al. (2018) | |
| Downregulated/Tumor suppressor gene | 45 patients with osteosarcoma/hFOB1.19, MG-63, U‐2OS, Saos‐2, HOS | - | - | Elevated amounts of LINC00511 slow the growth of tumors. LINC00511 could be a new indicator and prospective osteosarcoma treatment approach | Qiao et al. (2020) | |
| Upregulated/Oncogene | 10 TNTPs/hFOB 1.19, MG-63, HOS, Saos-2, 143B | LINC00511/miRNA- 618/MAEL axis | miRNA- 618/MAEL | OS cell growth and malignancy were both hindered by lower LINC00511 production. It could be a viable biomarker for more exploration on the treatment of OS. | Guo et al. (2019) | |
| T-cell Acute Lymphoblastic Leukemia (T-ALL) | Upregulated/Oncogene | Blood samples of 35 T-ALL patients and 30 normal controls/HPB-ALL, TALL-1, ALL-SIL, CUTLL1, PBMC | LINC00511/miR-195-5p/LRRK1 axis | miR-195-5p/LRRK1 | Through the miR-195-5p/LRRK1 axis, LINC00511 accelerated the evolution of T-ALL, pointing a possible therapeutic hint for the T-ALL sufferers | Li et al. (2020) |
| Glioma | Upregulated/Oncogene | HEB, NHA, T98 G cells (CRL-1690), A172 cells (CRL-1620), LN229 cells (CRL-2611), U-87MG cells (HTB-14IG) | LINC00511/miR-15a-5p/AEBP1 axis | miR-15a-5p/AEBP1 | Glioma formation can be slowed down by LINC00511 knockdown. Additionally, via the miR-15a-5p/AEBP1 axis, the process of LINC00511 influences the onset of glioma | Liu et al. (2021b) |
| Upregulated/Oncogene | U87, U251, SHG44, A172, NHA | SP1/LINC00511/miR‐124‐3p/CCND2 axis | miR‐124‐3p/CCND2 | The transcription factor SP1 served as the inspiration for the overexpression of LINC00511 in glioma cells. Additionally, the upregulation of LINC00511 competitively sponges the miR-124-3p, driving the production of CCND2 and the cyclin D2 protein produced by this gene, which may hold significant potential for glioma therapies | Li et al. (2019) | |
| Papillary Thyroid Carcinoma (PTC) | Upregulated/Oncogene | 41 TNTPs/B-CPAP, KTC-1, KTC-1 | - | CDKs and EZH2 | As an oncogene in PTC, LINC00511 promotes proliferation through CDKs. It will serve as a fundamental therapeutic target for PTC. | Xiang et al. (2020) |
| Colorectal Cancer (CRC) | Upregulated/Oncogene | 85 CRC tissues and adjacent normal tissues/HCT116, HT-29, LoVo, SW480, SW620, NCM460 | HNF4α/LINC00511/IL24 axis | HNF4α and IL24 | The proliferative, spreading and aggressive features of CRC cells are lowered by LINC00511 reduction, that eventually reduces tumorigenicity of CRC. | Lu et al. (2021) |
| Upregulated/Oncogene | 120 TNTPs/SW480, SW620, HCT16, HT29, NCM460 | LINC00511-mediated microRNA (miR)-625-5p/WEE1 axis | miRNA-625-5p/WEE1 | By suppressing WEE1 and restoring miR-625-5p, downregulated LINC00511 prevents the carcinogenesis of CC, establishing a fundamental standard for CC-targeted treatment | Qian et al. (2022) | |
| Upregulated/Oncogene | 12 TNTPs/HT-29, HCT8, HCE8693, SW620, NCM460 | LINC00511/miR-29c-3p/NFIA axis | miR-29c-3p/NFIA | By inhibiting the LINC00511/miR-29c-3p/NFIA axis, LINC00511 assisted in the onset of CRC, proposing that LINC00511 could be a viable therapeutic target. | Hu et al. (2020b) | |
| Glioblastoma (GBM) | Upregulated/Oncogene | 160 TNTPs/U87, A172, U138, U251, U373, LN‐18, T98G, Human HEK293T | Wnt/β-catenin signaling | miR‐126‐5p | In GBM cells, LINC00511 controlled Wnt/Catenin stimulation by functioning as a molecular sponge for miR-126-5p. It stated that LINC00511 could operate as a marker for the treatment of GBM. | Wang et al. (2021) |
| Upregulated/Oncogene | 36 GBM tissues and 8 non-tumour brain tissues (NBT)/U87, LN229, U251, A172, 293T | LINC00511/miR‐524‐5p/YB1/ZEB1 axis | miR‐524‐5p/YB1 | By boosting EMT, the LINC00511/miR524-5p/YB1/ZEB1 positive feedback loop might encourage GBM cell motility and infiltration. LINC00511 could be a viable therapeutic target for GBM sufferers | Du et al. (2020) | |
| Esophageal Cancer (ECa) | Upregulated/Oncogene | - | - | miR-150-5p | By attaching to miR-150-5p and sponging this miRNA, LINC00511 controls the creation of cancerous cells and, could be a treatment option for ECa | Sun et al. (2020a) |
| Cervical Cancer (CC) | Upregulated/Oncogene | - | LINC00511/miR-497-5p/MAPK1 axis | miR-497-5p/MAPK1 | Overexpression of LINC00511 boosted CC cell growth, motility and infiltration, whereas LINC00511 reduction had the opposite effects | Lu et al. (2022) |
| Upregulated/Oncogene | 92 cervical cancer tissues and 40 adjacent normal tissues/SiHa, HeLa, C33A, Caski, Ect1/E6E7 | - | - | In cervical cancer sufferers, high LINC00511 transcription is linked to clinical deterioration. The growth, motility and infiltration of tumor cells are restricted by LINC00511 suppression | Yu et al. (2019) | |
| Upregulated/Oncogene | 40 TNTPs/HT29, LOVO, SW620, SW480 | LINC00511/miR-153-5p/HIF-1α axis | miR-153-5p/HIF-1α | A crucial part of the CRC carcinogenesis is played by LINC00511. HIF-1α/LINC00511/miR-153-5p might be used as a therapeutic target in CRC. | Sun et al. (2020b) | |
| Upregulated/Oncogene | 19 TNTPs/SiHa, CaSki, C33A, HUCEC | LINC00511/miR-324-5p/DRAM1 axis | miR-324-5p/DRAM1 | The miR-324-5p/DRAM1 axis is regulated by LINC00511, acting as a ceRNA which, promotes the progression of both HPV-negative and HPV-positive cervical cancer | Zhang et al. (2020) | |
| Upregulated/Oncogene | 84 CC patients/PTX-resistant Hela/PTX | - | - | Suppression of LINC00511 may lessen CC cell motility and infiltration as well as paclitaxel tolerance, and may boost cell death in CC cells. LINC00511 suppression offers CC a brand-new treatment option | Mao et al. (2019) | |
| Upregulated/Oncogene | 47 TNTPs/SiHa, CaSki, C33A, ME180, HeLa, NCECs | - | RXRA or PLD1 | In CC, LINC00511 promotes the production of PLD1, which is controlled by RXRA. It could be a viable indicator for the therapy of CC. | Shi et al. (2020) | |
| Cervical Squamous Carcinoma (CESC) | Upregulated/Oncogene | 115 cases of CESC, 79 cases of cervical intraepithelial neoplasia and 101 healthy controls | - | - | A diagnostic model consisting of CCAT2 and LINC01133 has exhibited significant clinical utility for the identification of cervical intraepithelial neoplasia in both healthy individuals and patients. The serum concentrations of CCAT2, LINC01133 and LINC00511 could be used as effective non-invasive indicators for the diagnosis of CESC. | Wang et al. (2020b) |
| Clear Cell Renal Cell Carcinoma (ccRCC) | Upregulated/Oncogene | 49 TNTPs/HK-2, A498, 786-O, ACHN, Caki-2 | LINC00511/miR-625/CCND1 pathway | miRNA-625/cyclin D1 | As a ceRNA, LINC00511 controls the transcription of CCND1 in ccRCC via sponging miR-625. As a result, the LINC00511/miR-625/CCND1 pathway could offer ccrCC patients a prospective treatment approach | Deng et al. (2019) |
| Bladder Cancer (BcA) | Upregulated/Oncogene | 47 TNTPs/TCCSUP, SW780 | LINC00511/miR-143-3p/PCMT1 axis | miR-143-3p/PCMT1 | By suppressing the production of miR-143-3p and promoting the production of PCMT1, LINC00511s molecular mechanism may prevent bladder cancer cells from proliferating and invading. A novel target for bladder cancer treatment may be offered by LINC00511 | Dong et al. (2021) |
| Upregulated/Oncogene | 45 TNTPs/SV-HUC-1, BIU87, T24, 5637 | Wnt/β-catenin signaling pathway | miR-15a-3p | By inhibiting the Wnt/β-catenin signaling pathway activity, LINC00511 suppression decreases bladder cancer cells ability to proliferate and increases their likelihood of dying. LINC00511 could also be a putative bladder cancer indicator and possible therapeutic target. | Li et al. (2018) | |
| Tongue Squamous Cell Carcinoma (TSCC) | Upregulated/Oncogene | Tca-8113 | LINC00511/miR-765/LAMC2 axis | miR-765/LAMC2 | By sponging miR-765 with ceRNA, LINC00511 increases the production of LAMC2. the ceRNA regulation network contributes to new knowledge about the pathophysiology of TSCC and given information on how to take advantage of the emerging area of lncRNA-directed treatment for TSCC. | Ding et al. (2018) |
| Non-small Cell Lung Cancer (NSCLC) | Upregulated/Oncogene | 67 patients/16HBE, A549, NCIH1299, NCIH1650, NCIH 1975, NCIH460 | LINC00511/miR-625-5p/GSPT1 axis | miR-625-5p/GSPT1 | By targeting miR-625-5p/GSPT1, LINC00511 boosts NSCLC cell growth, infiltration and motility. LINC00511 is a possible diagnostic indicator and treatment option for NSCLC. | Cheng et al. (2021) |
| Upregulated/Oncogene | 57 TNTPs | - | EZH2 and LSD1/LATS2 and KLF2 | Apoptosis is triggered in NSCLC cells when LINC00511 is knocked down, although this reduces the capability of the cells to spread and infiltrate | Zhu et al. (2019) | |
| Upregulated/Oncogene | 62 stage I NSCLC patients and the age- and gender-matched healthy controls | LINC00511/miR-98-5p/TGFBR1 axis | miR-98-5p/TGFBR1 | In NSCLC, LINC00511 quantities were raised, which may contribute to distant postoperative recurrence of NSCLC and enhance NSCLC cell growth, motility and penetration by targeting and controlling the miR-98-5p/TGFBR1 axis | Li et al. (2022) | |
| Upregulated/Oncogene | 40 TNTPs/A549, H522, A549/DDP, H522/DDP, BEAS-2B | LINC00511/miR-625/LRRC8E pathway | miR-625/LRRC8E | LINC00511 enhanced LRRC8E production by downregulating miR-625 to boost DDP tolerance in NSCLC. A viable therapeutic target to reduce DDP tolerance in NSCLC is LINC00511 | Liu et al. (2022) | |
| Upregulated/Oncogene | 124 TNTPs/A549, SK-MES-1, H1299, 95D, H460, H520, H1975, H157, SK-LU-1, SPC-A-1, 16HBE | - | EZH2 and p57 | In NSCLC, LINC00511 is clinically, physiologically and molecularly oncogenic | Sun et al. (2016) | |
| Pancreatic Cancer (PC) | Upregulated/Oncogene | 91 TNTPs/BxPC-3, CFPAC-1, PANC-1, SW 1990, MIAPaCa-2, HPDE6-C7 | LINC00511/miR-370-5p/p21 Axis | miR-370-5p/p21, Snail, and ZEB1 | The LINC00511/miR-370-5p/p21 promoter region axis was responsible for the suppressive impact of DET (deoxyelephantopin) on the growth and spread of PC cells | Ji et al. (2022) |
| Pancreatic Ductal Adenocarcinoma (PDAC) | Upregulated/Oncogene | 140 TNTPs, PANC‐1, MIA PaCa‐2, Capan‐2, SW 1990, ASPC‐1, BxPC‐3, HPDE6 | LINC005/hsa‐miR29b‐3p/VEGFA axis | miR‐29b‐3p/VEGFA | The etiology of PDAC is profoundly influenced by the new lncRNA LINC00511. LINC00511 is a unique predictive indicator that can forecast the clinical outcomes of PDAC sufferers following surgery and could be used as a treatment option for PDAC. | Zhao et al. (2018) |
| Thyroid Carcinoma (TC) | Upregulated/Oncogene | TPC-1, BCPAP, IHH-4, Nthy-ori 3–1 | JAK2/STAT3 signaling pathway and LINC00511/TAF1/JAK2 axis | TAF1 and JAK2 | Through TAF1-mediated JAK2/STAT3 signaling, enhanced expression of LINC00511 increased the radiosenitivity of TC cells. The potential biomarker function of LINC00511 in the management of TC was shown by the recent research | Chen et al. (2019b) |
| Ovarian Cancer (OC) | Upregulated/Oncogene | CAOV3, OVCAR3, SKOV3, UWB1.289 | - | miR-424-5p and miR-370-5p/ESR1 | With the suppression of cell death, upregulated LINC00511 boosted the vitality, motility and penetration of CAOV3 cells. The disruption of miR-424-5p and miR-370-5p is likely responsible for these actions that promote malignancy | Wang et al. (2019b) |
| Upregulated/Oncogene | SKOV3, SNU840 | - | EZH2 and P21 | The growth of OC cells is slowed by LINC00511 silencing. This information may offer a valuable lncRNA as a predictive indicator and possible treatment option | Deng et al. (2019) |